CanBas Co., Ltd.

$4.70

$0.28(-5.56%)

CanBas Co., Ltd.

4575.T

$4.70

$0.28(-5.56%)

CanBas Co., Ltd.

4575.T

JPX

$4.70

$0.28(-5.56%)

Chart

Upcoming Earnings

Next report date

May 8, 2026

Report period

Q2 2026

EPS Estimate

—

Revenue Estimate

—

Key stats

52-Week Range$4.70

$4.57

$9.75

Market capitalization

$96.41M

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-13.21

Basic EPS (TTM)

$-0.40

Net income (TTM)

$-7.80M

Revenue (TTM)

$0.00

Avg. volume

291.64K

Beta (1Y)

-1.22

Employees

Market capitalization

$96.41M

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-13.21

Basic EPS (TTM)

$-0.40

Net income (TTM)

$-7.80M

Revenue (TTM)

$0.00

Avg. volume

291.64K

Beta (1Y)

-1.22

Employees

Screener Quick Check

About CanBas Co., Ltd.

Sector

Healthcare

Industry

Biotechnology

CEO

Takumi Kawabe

Website

www.canbas.co.jp

Headquarters

2-2-1, Otemachi, Numazu, 410-0801

IPO Date

2009-09-17

Identifiers

ISINJP3244570002

Description

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501,...

Related Stocks

Oncolys BioPharma Inc.

4588.T

$17.15Mkt Cap: $426.16M

Healthcare

Biotechnology

ISIN:JP3202170001

Medical Data Vision Co., Ltd.

3902.T

$10.54Mkt Cap: $398.91M

Healthcare

Medical - Healthcare Information Services

ISIN:JP3921250001

Dividend Overview

This company does not pay dividends

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q2 '26

Actual

Estimate

Earnings

Next: Q2 '26

Actual

Estimate